Apogee Therapeutics (APGE) is in focus after releasing interim Phase 1b data for its asthma drug candidate zumilokibart, ...

Apogee Therapeutics reports early trial data showing its asthma drug APG777 sharply reduced a key inflammation marker for up ...

Investors in Apogee Therapeutics Inc (Symbol: APGE) saw new options become available this week, for the October 17th expiration. One of the key inputs that goes into the price an option buyer is ...

Investors in Apogee Therapeutics Inc (Symbol: APGE) saw new options become available today, for the December 2025 expiration. One of the key data points that goes into the price an option buyer is ...

Fintel reports that on January 7, 2026, Wolfe Research initiated coverage of Apogee Therapeutics (NasdaqGM:APGE) with a Peer ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. Apogee Therapeutics, Inc. stands fourth on our list. Apogee Therapeutics, Inc. (NASDAQ:APGE) is a clinical-stage biotech company ...

Apogee Therapeutics, Inc. (APGE) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

Apogee Therapeutics Inc. (NASDAQ:APGE) stock is experiencing a significant surge, trading almost 29% higher in premarket on Monday. This substantial increase in stock price follows the release of ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing and potential applications in asthma, COPD, and psoriasis. APGE's investigational pipeline includes ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best oversold NASDAQ stocks to buy now. On July 11, BTIG analyst Julian Harrison maintained a Buy rating on Apogee Therapeutics Inc. (NASDAQ:APGE), ...